Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Educators Post Observer.
Headshot Photographer in Las Vegas Offers Studio-Quality Lighting On Location
EIN Presswire
·
June 23, 2025
Las Vegas headshot photographer Christian Purdie brings studio-quality lighting to businesses and professionals through on-location photography sessions. LAS VEGAS, NV, UNITED STATES, June 23, 2025 /EINPresswire.com/ -- As the need for...
Only Natural Student Design Competition Winners to be part of Material Matters Showcase at London Design Festival
EIN Presswire
·
June 23, 2025
- Entrants to use only natural materials to design a fashion or home piece - Last call for entries *30 June* - https://onlynatural.internationaldesigncomp.com/ LONDON, UNITED KINGDOM, June 23, 2025 /EINPresswire.com/ -- Only Natural Winners to...
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
GlobeNewswire, Inc.
·
June 23, 2025
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company...
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
GlobeNewswire, Inc.
·
June 23, 2025
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at...
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
GlobeNewswire, Inc.
·
June 23, 2025
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) and 53%...
Education 2.0 Conference Highlights How Online Reviews Mislead Students & Parents
EIN Presswire
·
June 23, 2025
Education 2.0 Conference 2025 will spotlight how misleading online reviews impact student choices, urging smarter, research-driven educational decisions. DUBAI, DUBAI, UNITED ARAB EMIRATES, June 23, 2025 /EINPresswire.com/ -- The upcoming...
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
GlobeNewswire, Inc.
·
June 23, 2025
Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2 Fremanezumab demonstrated sustained effectiveness and a favourable safety and...
LEADING EDGE MATERIALS' INVESTOR UPDATE AND SIGNIFICANT ACTIVITIES
GlobeNewswire, Inc.
·
June 23, 2025
LEADING EDGE MATERIALS’ INVESTOR UPDATE ON SIGNIFICANT ACTIVITIES Vancouver, June 22, 2025 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) provides an investor...
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
GlobeNewswire, Inc.
·
June 23, 2025
Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) --...
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
GlobeNewswire, Inc.
·
June 23, 2025
Breakthrough Therapy Designation based on promising early clinical evidence observed with daraxonrasib in patients with pancreatic ductal adenocarcinoma (PDAC) RASolute 302, a Phase 3 registrational study of daraxonrasib in patients with...
BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers
GlobeNewswire, Inc.
·
June 23, 2025
Head-to-head study comparing BioREtain®- processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 POMPANO BEACH, Fla., June...
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
GlobeNewswire, Inc.
·
June 23, 2025
New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity Rejuva-treated healthy animals exposed to a high fat diet were protected from weight gain and hyperglycemia Data reinforce...
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza
GlobeNewswire, Inc.
·
June 23, 2025
The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo...
Automotive Lightweight Material Market Set to Reach USD 47.32 Billion by 2035
EIN Presswire
·
June 21, 2025
Analysis of Automotive Lightweight Material Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries ROCKVILLE , MD, UNITED STATES, June 21, 2025 /EINPresswire.com/ -- The global automotive...
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO APRIL 30, 2025
GlobeNewswire, Inc.
·
June 20, 2025
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO APRIL 30, 2025 Vancouver, June 20, 2025 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) announces...
NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer’s Trial with Activation of Clinical Sites in Canada and Florida
GlobeNewswire, Inc.
·
June 23, 2025
SANTA ANA, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic...
Humidity-resistant phosphorescent films achieved through crosslinking reaction
EIN Presswire
·
June 23, 2025
GA, UNITED STATES, June 23, 2025 /EINPresswire.com/ -- Researchers have developed a humidity-resistant phosphorescent material using a simple and effective strategy of multi-component crosslinking in polyvinyl alcohol (PVA) films. The innovation...
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
GlobeNewswire, Inc.
·
June 23, 2025
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in...
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
GlobeNewswire, Inc.
·
June 23, 2025
Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived...
NTE Announces Closed Beta Test for 3 July During Livestream Showcase
GlobeNewswire, Inc.
·
June 23, 2025
BEIJING, June 23, 2025 (GLOBE NEWSWIRE) -- Publisher Perfect World Games, and Hotta Studio, developers of the highly-anticipated, supernatural urban open-world RPG NTE (Neverness to Everness), have announced a new Closed Beta test for Windows PC,...